Ser380
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser380  -  p90RSK (human)

Site Information
HQLFRGFsFVAtGLM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447990
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 43 ) , immunoprecipitation ( 3 , 5 , 7 , 9 , 44 , 101 ) , mass spectrometry ( 4 , 6 , 10 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 37 , 38 , 39 , 40 , 41 , 45 , 46 , 47 , 51 , 52 , 53 , 54 , 55 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 102 , 104 , 110 ) , mutation of modification site ( 7 , 9 , 107 ) , phospho-antibody ( 1 , 2 , 3 , 5 , 7 , 8 , 9 , 11 , 16 , 35 , 36 , 43 , 44 , 49 , 50 , 72 , 101 , 103 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 ) , western blotting ( 1 , 2 , 3 , 5 , 7 , 8 , 9 , 11 , 35 , 36 , 44 , 49 , 50 , 101 , 103 , 105 , 106 , 107 , 108 , 109 , 110 , 112 , 116 , 117 , 118 )
Disease tissue studied:
breast cancer ( 13 , 14 , 24 , 49 , 101 , 112 , 116 ) , breast ductal carcinoma ( 13 ) , HER2 positive breast cancer ( 6 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, surrounding tissue ( 6 ) , breast cancer, triple negative ( 6 , 13 ) , cervical cancer ( 79 ) , cervical adenocarcinoma ( 79 ) , colorectal cancer ( 5 , 7 , 16 , 104 ) , colorectal carcinoma ( 5 , 7 , 16 , 104 ) , gastric cancer ( 54 , 71 , 87 , 88 , 89 ) , gastric carcinoma ( 54 , 71 , 87 , 88 , 89 ) , leukemia ( 1 , 69 , 70 , 97 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 23 ) , acute myeloblastic leukemia, without maturation (M1) ( 23 ) , chronic myelogenous leukemia ( 69 , 70 , 97 ) , T cell leukemia ( 1 ) , liver cancer ( 74 , 75 , 76 , 108 ) , liver cancer, surrounding tissue ( 73 , 77 ) , lung cancer ( 8 , 24 , 47 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 80 , 81 , 85 , 86 , 98 , 99 , 100 ) , non-small cell lung cancer ( 8 , 24 , 62 , 63 , 64 , 65 , 66 , 68 , 80 , 81 , 85 , 86 , 99 , 100 ) , non-small cell lung adenocarcinoma ( 8 , 86 ) , non-small cell squamous cell lung carcinoma ( 86 ) , lung cancer, surrounding tissue ( 84 ) , lymphoma ( 15 , 36 , 105 ) , anaplastic large cell lymphoma ( 36 ) , B cell lymphoma ( 23 ) , Burkitt's lymphoma ( 15 ) , non-Hodgkin's lymphoma ( 23 ) , follicular lymphoma ( 15 ) , mantle cell lymphoma ( 15 ) , T cell lymphoma ( 105 ) , ovarian cancer ( 13 ) , multiple myeloma ( 23 ) , prostate cancer ( 50 , 106 , 108 ) , melanoma skin cancer ( 10 , 57 , 58 , 59 , 60 , 61 ) , psoriasis ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) [Raptor (human), transfection] ( 44 ) , 293 (epithelial) ( 7 , 72 ) , 293E (epithelial) ( 103 , 110 ) , A498 (renal) ( 55 ) , A549 (pulmonary) ( 19 ) , BaF3 ('B lymphocyte, precursor') [RSK3 (human)] ( 102 ) , BJAB (B lymphocyte) ( 15 ) , breast ( 6 , 13 ) , BT-20 (breast cell) ( 24 ) , C2BBe1 (intestinal) ( 9 ) , Caco-2 (intestinal) ( 5 ) , chromaffin-adrenal gland ( 117 ) , CL1-1 (pulmonary) ( 47 ) , CL1-2 (pulmonary) ( 47 ) , CL1-5 (pulmonary) ( 47 ) , CTS (myeloid) ( 23 ) , DOHH2 ('B lymphocyte, precursor') ( 23 ) , GM03317 ( 113 ) , H2009 (pulmonary) ( 11 , 24 ) , H2887 (pulmonary) ( 24 ) , HCC1937 (breast cell) ( 24 , 101 ) , HCC827 (pulmonary) ( 8 ) , HCT116 (intestinal) ( 90 , 104 ) , HCT15 (intestinal) ( 16 ) , HeLa (cervical) ( 4 , 7 , 12 , 22 , 35 , 46 , 82 , 91 , 94 , 103 , 107 , 108 , 114 ) , HeLa S3 (cervical) ( 79 , 93 , 107 ) , HeLa_Meta (cervical) ( 53 ) , HeLa_Pro (cervical) ( 53 ) , HeLa_Telo (cervical) ( 53 ) , HepG2 (hepatic) ( 108 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 14 ) , HMLER ('stem, breast cancer') ( 14 ) , HUES-9 ('stem, embryonic') ( 45 ) , HUT-78 (T lymphocyte) ( 105 ) , JB-6 (lymphocyte) ( 36 ) , JEKO-1 (B lymphocyte) ( 15 ) , Jurkat (T lymphocyte) ( 1 , 20 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 37 , 38 , 39 , 40 , 41 , 51 , 52 , 78 , 92 , 95 , 96 , 104 , 105 ) , K562 (erythroid) ( 22 , 69 , 70 , 97 ) , KATO III (gastric) ( 89 ) , liver ( 18 , 73 , 74 , 75 , 76 , 77 ) , LNCaP (prostate cell) ( 50 , 106 ) , lung ( 8 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 80 , 81 , 84 , 85 , 98 , 99 , 100 ) , macrophage-bone marrow ( 2 ) , MCF-7 (breast cell) ( 24 , 112 ) , MDA-MB-231 (breast cell) ( 101 , 116 ) , MDA-MB-435S (breast cell) ( 90 ) , MDA-MB-468 (breast cell) ( 24 , 101 ) , MES (pulmonary) ( 111 ) , mesangial ( 109 ) , mesothelial ( 111 ) , MKN-45 (gastric) ( 54 , 71 , 87 , 88 ) , MOLT-4 (T lymphocyte) ( 105 ) , monocyte-blood ( 2 ) , MSTO-211H (mesothelial) ( 113 ) , MV4-11 (macrophage) ( 23 , 90 ) , NCI-H157 (pulmonary) ( 24 ) , NCI-H1666 (pulmonary) ( 24 ) , NCI-H1703 (squamous) ( 86 ) , neutrophil ( 118 ) , OCI-ly1 (B lymphocyte) ( 15 ) , OPM-2 (plasma cell) ( 23 ) , ovary ( 13 ) , P31/FUJ (erythroid) ( 23 ) , PC3 (prostate cell) ( 108 ) , PC9 (pulmonary) ( 8 ) , Raji (B lymphocyte) ( 15 ) , RAMOS (B lymphocyte) ( 15 ) , RL ('B lymphocyte, precursor') ( 23 ) , RPMI-8266 (plasma cell) ( 23 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 17 ) , skin ( 3 , 57 , 58 , 59 , 60 , 61 ) , SU-DHL-4 (B lymphocyte) ( 15 ) , SU-DHL-6 (B lymphocyte) ( 23 ) , SUM159 (breast cell) ( 101 ) , SW48 (intestinal) ( 16 ) , SW480 (intestinal) ( 7 ) , SW620 (intestinal) ( 16 ) , T lymphocyte-blood ( 26 ) , T47D (breast cell) ( 49 ) , U266 (plasma cell) ( 23 ) , WM239A (melanocyte) ( 10 )

Upstream Regulation
Regulatory protein:
CK2A1 (human) ( 35 ) , PKCE (human) ( 50 ) , PLCE1 (human) ( 5 ) , TIMP1 (human) ( 11 )
Kinases, in vitro:
Cot (human) ( 83 )
Treatments:
AG1478 ( 116 ) , ALW-II-41-27 ( 8 ) , angiotensin ( 117 ) , anti-CD3 ( 26 ) , atazanavir ( 2 ) , CTGF ( 109 ) , dronabinol ( 105 ) , EGF ( 36 , 49 , 82 , 101 , 106 , 110 ) , estrogen_deprivation ( 112 ) , fluoromethylketone ( 107 ) , FMK-MEA ( 2 , 16 ) , fMLP ( 118 ) , H2O2 ( 2 ) , ionizing_radiation ( 116 ) , ischemia ( 13 ) , LPA ( 5 , 9 , 55 ) , LY294002 ( 106 ) , Maraviroc ( 2 ) , metastatic potential ( 47 ) , MG132_withdrawal ( 53 ) , nicotine ( 111 ) , PD0325901 ( 16 ) , PD184352 ( 44 ) , PD98059 ( 101 , 116 , 118 ) , phorbol_ester ( 44 , 50 , 101 , 103 ) , pictilisib ( 1 ) , PP1 ( 117 ) , PP242 ( 16 ) , rapamycin ( 103 ) , ritonavir ( 2 ) , SB202190 ( 82 ) , SCH772984 ( 1 ) , selumetinib ( 10 ) , serum ( 101 , 106 , 107 ) , serum_starvation ( 106 ) , SP600125 ( 108 ) , TBB ( 35 ) , Tenofovir ( 2 ) , TNF ( 5 , 48 ) , tPA ( 35 ) , Trametinib ( 5 ) , U0126 ( 5 , 35 , 44 , 49 , 82 , 103 , 106 , 117 ) , UV ( 113 ) , vemurafenib ( 10 ) , wortmannin ( 49 , 118 )

Downstream Regulation
Effects of modification on p90RSK:
phosphorylation ( 2 )
Effects of modification on biological processes:
signaling pathway regulation ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
HNSCC ( 43 ) , psoriasis ( 3 )

References 

1

Nováková J, Talacko P, Novák P, Vališ K (2019) The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells. Cells 8
30795621   Curated Info

2

Singh MV, et al. (2018) Senescent Phenotype Induced by p90RSK-NRF2 Signaling Sensitizes Monocytes and Macrophages to Oxidative Stress in HIV Individuals: Implications for Atherogenesis. Circulation
30586719   Curated Info

3

Rasmussen MK, et al. (2017) Protein phosphatase 2Cδ/Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin. J Inflamm Res 10, 169-180
29290690   Curated Info

4

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

5

Wakita M, et al. (2016) Phospholipase Cϵ Activates Nuclear Factor-κB Signaling by Causing Cytoplasmic Localization of Ribosomal S6 Kinase and Facilitating Its Phosphorylation of Inhibitor κB in Colon Epithelial Cells. J Biol Chem 291, 12586-600
27053111   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Lim HC, Jou TS (2016) Ras-activated RSK1 phosphorylates EBP50 to regulate its nuclear localization and promote cell proliferation. Oncotarget 7, 10283-96
26862730   Curated Info

8

Amato KR, et al. (2016) EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res 76, 305-18
26744526   Curated Info

9

No YR, He P, Yoo BK, Yun CC (2015) Regulation of NHE3 by lysophosphatidic acid is mediated by phosphorylation of NHE3 by RSK2. Am J Physiol Cell Physiol 309, C14-21
25855080   Curated Info

10

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

11

Nalluri S, et al. (2015) TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2. PLoS One 10, e0137673
26366732   Curated Info

12

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

13

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

14

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

15

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

16

Ducker GS, et al. (2014) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 33, 1590-600
23542178   Curated Info

17

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

18

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

19

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

20

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

21

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

22

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

23

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

24

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

25

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

26

Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA (2012) Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics 11, 171-86
22499768   Curated Info

27

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

28

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Mulhern D (2011) CST Curation Set: 13068; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

30

Mulhern D (2011) CST Curation Set: 13069; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

31

Mulhern D (2011) CST Curation Set: 13070; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

32

Mulhern D (2011) CST Curation Set: 13071; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

33

Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

34

Mulhern D (2011) CST Curation Set: 12713; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

35

Plotnikov A, et al. (2011) Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol Cell Biol 31, 3515-30
21730285   Curated Info

36

Lau AT, et al. (2011) Phosphorylation of histone H2B serine 32 is linked to cell transformation. J Biol Chem 286, 26628-37
21646345   Curated Info

37

Guo A (2011) CST Curation Set: 11989; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

38

Guo A (2011) CST Curation Set: 11884; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

39

Guo A (2011) CST Curation Set: 11886; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

40

Guo A (2011) CST Curation Set: 11887; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

41

Guo A (2011) CST Curation Set: 11888; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

42

Peng C, et al. (2011) Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J Biol Chem 286, 6946-54
21183680   Curated Info

43

Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info

44

Carriere A, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286, 567-77
21071439   Curated Info

45

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

46

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

47

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

48

Peng C, et al. (2010) RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. FASEB J 24, 3490-9
20385620   Curated Info

49

Aksamitiene E, et al. (2010) PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22, 1369-78
20471474   Curated Info

50

Meshki J, et al. (2010) Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway. J Biol Chem 285, 26033-40
20566643   Curated Info

51

Possemato A (2010) CST Curation Set: 10140; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

52

Possemato A (2010) CST Curation Set: 9918; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

53

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

54

Moritz A (2010) CST Curation Set: 9924; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

55

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

56

Wang H, Moreau F, Hirota CL, MacNaughton WK (2010) Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. FASEB J 24, 1971-80
20065107   Curated Info

57

Tucker M (2010) CST Curation Set: 9779; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

58

Tucker M (2010) CST Curation Set: 9778; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

59

Tucker M (2010) CST Curation Set: 9777; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

60

Tucker M (2010) CST Curation Set: 9780; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

61

Tucker M (2010) CST Curation Set: 9781; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

62

Rikova K (2010) CST Curation Set: 9470; Year: 2010; Biosample/Treatment: tissue, /untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

63

Rikova K (2010) CST Curation Set: 9468; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

64

Rikova K (2010) CST Curation Set: 9460; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

65

Rikova K (2010) CST Curation Set: 9456; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

66

Rikova K (2010) CST Curation Set: 9454; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

67

Rikova K (2010) CST Curation Set: 9469; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

68

Rikova K (2010) CST Curation Set: 9458; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

69

Rikova K (2010) CST Curation Set: 9327; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

70

Rikova K (2010) CST Curation Set: 9326; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

71

Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

72

Julien LA, Carriere A, Moreau J, Roux PP (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30, 908-21
19995915   Curated Info

73

Tucker M (2010) CST Curation Set: 8913; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

74

Tucker M (2010) CST Curation Set: 8910; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

75

Tucker M (2010) CST Curation Set: 8908; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

76

Tucker M (2010) CST Curation Set: 8914; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

77

Tucker M (2010) CST Curation Set: 8915; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

78

Moritz A (2010) CST Curation Set: 8865; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

80

Rikova K (2009) CST Curation Set: 8551; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

81

Rikova K (2009) CST Curation Set: 8553; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

82

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

83

Wu B, Jiang P, Mu Y, Wilmouth RC (2009) Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210. Biol Chem 390, 1271-7
19804365   Curated Info

84

Rikova K (2009) CST Curation Set: 8511; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

85

Rikova K (2009) CST Curation Set: 8513; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

86

Possemato A (2009) CST Curation Set: 8409; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

87

Possemato A (2009) CST Curation Set: 8412; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

88

Possemato A (2009) CST Curation Set: 8411; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

89

Possemato A (2009) CST Curation Set: 8413; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

90

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

91

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

92

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

93

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

94

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

95

Possemato A (2008) CST Curation Set: 4829; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

96

Possemato A (2008) CST Curation Set: 4830; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

97

Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

98

Rikova K (2008) CST Curation Set: 4102; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

99

Rikova K (2008) CST Curation Set: 4103; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

100

Rikova K (2008) CST Curation Set: 4104; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

101

Stratford AL, et al. (2008) Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10, R99
19036157   Curated Info

102

Kang S, et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12, 201-14
17785202   Curated Info

103

Roux PP, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282, 14056-64
17360704   Curated Info

104

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info

105

Jia W, et al. (2006) Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 4, 549-62
16908594   Curated Info

106

Chao OS, Clément MV (2006) Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells. Oncogene 25, 4458-69
16767165   Curated Info

107

Shahbazian D, et al. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25, 2781-91
16763566   Curated Info

108

Huang W, et al. (2006) Selective repression of low-density lipoprotein receptor expression by SP600125: coupling of histone H3-Ser10 phosphorylation and Sp1 occupancy. Mol Cell Biol 26, 1307-17
16449644   Curated Info

109

Wahab NA, Weston BS, Mason RM (2005) Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16, 340-51
15601748   Curated Info

110

Ballif BA, et al. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A 102, 667-72
15647351   Curated Info

111

Trombino S, et al. (2004) Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 64, 135-45
14729617   Curated Info

112

Martin LA, et al. (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278, 30458-68
12775708   Curated Info

113

Zhang Y, et al. (2003) Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. J Biol Chem 278, 12650-9
12562765   Curated Info

114

Takahashi-Yanaga F, et al. (2003) Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem 278, 9663-70
12522140   Curated Info

115

Ehses JA, Pelech SL, Pederson RA, McIntosh CH (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277, 37088-97
12138104   Curated Info

116

Amorino GP, et al. (2002) Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 13, 2233-44
12134064   Curated Info

117

Cammarota M, Bevilaqua LR, Dunkley PR, Rostas JA (2001) Angiotensin II promotes the phosphorylation of cyclic AMP-responsive element binding protein (CREB) at Ser133 through an ERK1/2-dependent mechanism. J Neurochem 79, 1122-8
11752053   Curated Info

118

De Mesquita DD, Zhan Q, Crossley L, Badwey JA (2001) p90-RSK and Akt may promote rapid phosphorylation/inactivation of glycogen synthase kinase 3 in chemoattractant-stimulated neutrophils. FEBS Lett 502, 84-8
11583116   Curated Info